Cardinal Logo  
Lab Briefings Banner
Webinar lab

Cardinal Health sponsors continuing medical educational events for healthcare professionals across the country. You can register for upcoming sessions here, or watch archived webinar recordings at any time, from anywhere. These Cardinal Health sponsored events are presented by esteemed professionals in the world of healthcare and research, and managed by Whitehat Communications to ensure a professional environment. Attend these basic level webinars at no cost - all offer one P.A.C.E.® Continuing Education contact hour for up to six months after the live event. Be sure to check back often for new event postings. For information on Cardinal Health laboratory products, please visit our website here.

Payor Audits – Preparing your Laboratory
Live Event: Wednesday, February 27, 2019  1:00 - 2:00 PM EST
PACE® Credit available until August 27, 2019  |  Florida Lab Credit available
Labs are under increasing scrutiny from government and commercial payors, and audit and recoupment actions are on the rise. Labs are charged with taking reasonable steps to ensure they are submitting claims for services that are reasonable and necessary and not for those that are not covered. When it is not possible to support medical justification for testing or provide appropriate documentation of claims, labs are vulnerable to recoupment actions. Furthermore, a laboratory subject to an audit is considered to be in possession of credible information of an overpayment and must initiate a review as required by the Reverse False Claims Rule (also referred to as the 60-Day Rule).

This presentation will help participants better understand the payor audit process and prepare the organization to respond. From recognizing the significance of initial correspondence to responding effectively to initial and subsequent rounds of review, the presentation will take participants through the payor audit process from a government perspective and compare and contrast typical government audits with typical commercial audits. This presentation will also provide labs with information on the Reverse False Claims Rule/60 Day Rule. Finally, the presentation will identify some best practices that labs can implement now to prepare for payor audits.

This webinar will:
  • Describe the government audit process from initial correspondence through the various stages of appeal and share speakers’ experience with respect to commercial payor audits, i.e., what is similar and what is different from government audits and explore recent case law regarding lab audits
  • Discuss the lab’s responsibilities with respect to the medical necessity of testing for which it is submitting claims
  • Examine the lab’s duties with respect to the Reverse False Claims/60 Day Rule following an audit request
  • Identify steps labs can take to prepare for audits prior to an audit being initiated
Disclaimer: The information in this presentation is provided for educational purposes only and is not legal advice. It is intended to highlight laws you are likely to encounter, but is not a comprehensive review. If you have questions or concerns about a particular instance or whether a law applies, you should consider contacting your attorney.
Liz Sullivan photo  Elizabeth Sullivan, Member McDonald Hopkins LLC 
Liz is a co-chair of the National Healthcare Practice at McDonald Hopkins, LLC.
She has assisted clinical laboratories, hospitals, pathology groups and many other healthcare providers on regulatory, licensing, compliance, reimbursement, contractual, and corporate matters.
Blue line
Courtney Tito photo  Courtney Tito, Attorney McDonald Hopkins LLC
Courtney is a member of the Health Law group at McDonald Hopkins, LLC in its West Palm Beach office.  
She counsels and represents clients in a variety of health law areas, including, federal and private payor audits and disputes, reimbursement, contract, corporate, enrollment revocations, payment suspensions, and many others.
Reimbursement & Policy Outlook for Labs in 2019
Live Event: Wednesday, January 30, 2019  1:00 - 2:00 PM EST
PACE® Credit available until July 30, 2019  |  Florida Lab Credit available
Recording Slides
For the clinical laboratory industry, look for 2019 to be another challenging year on the reimbursement front as a second round of Medicare cuts of up to 10 percent for many lab tests take effect under a market-based fee schedule required by the Protecting Access to Medicare Act (PAMA). Even as the American Clinical Laboratory Association (ACLA) appeals a federal court decision upholding PAMA, the Centers for Medicare & Medicaid Services (CMS) moved to require most hospital labs to start reporting private payor data during the next scheduled reporting period: Jan 1 to June 20, 2019. At the same time, industry interests are supporting a legislative strategy to get Congress to mitigate future PAMA cuts.

Meanwhile, federal oversight of laboratory developed tests (LDTs) remains in limbo with the Food & Drug Administration signaling that Congress should take the lead, leaving it to key legislators to formulate a consensus bill. In addition, CMS is weighing industry feedback to announcements seeking public comment on whether to revise certain regulatory requirements under CLIA and the Stark self-referral law. Finally, the Trump Administration is moving ahead with administrative changes to dilute consumer protections under the Affordable Care Act despite a newly divided Congress starting in 2019. Find out how these policy shifts and other key national trends are affecting the way labs conduct business.

This webinar will:
  • Assess the current reimbursement environment for clinical laboratories in light of the ongoing cuts being made by Medicare and their impact on commercial insurers
  • Understand the differing industry legal and legislative strategies involving PAMA plus the congressional outlook for modifying the law
  • Examine what recent steps FDA has taken affecting laboratory developed tests (LDTs) and the outlook for LDT action on Capitol Hill
  • Discuss changes in CLIA and Stark self-referral requirements being considered by CMS and the timetable for further action
Dennis Weissman
President, Dennis Weissman & Associates, LLC
Dennis Weissman Photo
A nationally known, independent analyst, consultant and thought leader for the clinical laboratory and anatomic pathology sectors for over three decades, Dennis is President of Dennis Weissman & Associates, LLC, Falls Church, VA, a consultancy which provides market intelligence, M&A advisory services, business leadership and public policy advice to diagnostic and life science companies and organizations. Mr. Weissman has expertise in Medicare and health care reform policies and trends; clinical laboratory and pathology payment & compliance policies as well as business trends affecting the diagnostic sector.
Laboratory Stewardship Essentials
Live Event: Tuesday, December 11, 2018  1:00 - 2:00 PM EST
PACE® Credit available until June 11, 2019  |  Florida Lab Credit available
  Recording Slides
As the healthcare industry transitions from fee for service to value based reimbursement, hospital systems are challenged to improve quality while reducing costs. While laboratory spending only accounts for 2-3% of overall healthcare costs, the laboratory drives 70-80% of downstream medical decisions1,2. For this reason, proper laboratory stewardship is a critical in today’s healthcare industry.

This webinar will explore essential steps to establish an effective lab stewardship program including governance and structure of stewardship committees. Dr. Fletcher will also outline strategies for implementing successful laboratory stewardship interventions. These strategies include consolidation of reference testing for cost reduction and improved turn-around time, reference test formulary development to limit inappropriate inpatient tests - and appropriate utilization of in-house testing including discussion on the impact of order-sets, recurring daily lab tests and duplicate lab tests. Each of these strategies will drive downstream savings and improve the quality of patient care in healthcare systems. 

1Donaldson K, Young D. An evidentiary rules-based approach to reducing unnecessary lab testing. Am J Clin Pathol. 2010;134:503
2Forsman RW. Why is the laboratory an afterthought for managed care organizations? Clin Chem 1996;42:813–6.

This webinar will:
  • Describe ways to establish a Laboratory Stewardship program with appropriate governance and engage ordering physicians
  • Develop and implement a reference laboratory test formulary
  • Identify opportunities and strategies to reduce duplicate and daily in-house tests
  • Formulate strategies to minimize downstream costs through appropriate testing

Andrew Fletcher, MD, CPE
Medical Director, Consultative Services
Andrew Fletcher Photo
Dr. Fletcher is a board-certified anatomic/clinical pathologist and certified physician executive with significant experience in leading quality across an organization and reducing clinical variation to effectively drive safety and value. He has a doctor of medicine degree from the Mercer University School of Medicine in Georgia and is currently pursuing his MBA from the University of Massachusetts at Amherst. Dr. Fletcher has received numerous awards for quality and utilization, including research grants for blood utilization.
Be Inspection Ready with the 2018 CAP Accreditation Checklists
Live Event: Thursday, November 15, 2018  1:00 - 2:00 PM EST
PACE® Credit available until May 15, 2019  |  Florida Lab Credit available
Recording Slides
The College of American Pathologists (CAP) Laboratory Accreditation Program checklists are updated regularly to keep laboratories on the forefront of the latest regulatory requirements and technological advances to ensure accurate and reliable laboratory processes. The most recent checklist edition, published August 2018, is now in the field for CAP laboratory inspections. This checklist includes nearly 3,000 requirements organized into 21 checklists which are used as a guide to assess the laboratory’s overall management and operation.

Join this webinar for insight into the latest revisions to the CAP Laboratory Accreditation Program checklist requirements and use CAP resources to identify checklist updates. You will learn how these updates will impact the inspection process, discover the rationale behind the changes and receive helpful guidance for implementation in your own laboratory.

This webinar will:
  • Describe key changes to the 2018 CAP Accreditation Checklist edition
  • Interpret the rationale for the changes made to the checklist
  • Use CAP resources to identify and understand key changes
  • Recognize and implement necessary changes to ensure compliance with new accreditation requirements

William West Photo  William W. West, MD, FCAP
Chair, College of American Pathologists Checklists Committee

Dr. West is a pathologist at CHI Health/Creighton University Medical Center in Omaha, Nebraska. He is currently Chair of the College of American Pathologists Checklists Committee and member of the Commission on Laboratory Accreditation.
Blue Line 
Harris Goodman Photo  Harris Goodman, MD, FCAP, Vice-Chair, College of American Pathologists Checklists Committee

Dr. Goodman attended University of California at San Francisco for medical school and residency in pathology and laboratory medicine and is board certified in anatomic pathology, clinical pathology, and cytopathology.
Discovering the Optimal Approach to Diagnosing Clostridium difficile Infection
Live Event: Wednesday, October 24, 2018  1:00 - 2:00 PM EST
PACE® Credit available until April 24, 2019  |  Florida Lab Credit available
Recording Slides
Clostridium difficile infection (CDI) is the most common healthcare-associated infection in the United States. In 2011, the Centers for Disease Control and Prevention (CDC) estimated 500,000 cases and more than 29,000 deaths were caused by C. difficile. To combat this growing health problem, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) updated their clinical practice guideline for CDI. This guideline serves as an important resource for the medical, infection prevention and public health communities1

This webinar will discuss the clinical background of CDI and the role of molecular testing that is used by more than 70% of hospital laboratories. Molecular testing can not only help rule out CDI but also help reduce CDI transmission by detecting CDI in patients2. We will discuss the incidence, role, and clinical impact of C. difficile as a human pathogen. Also discussed will be the impact of the modified CDC’s National Healthcare Safety Network (NHSN) guidelines on public reporting of C. difficile cases in the United States. We will also review testing options including molecular diagnostics, recommended treatments, and prevention measures in the hospital setting.

1Updated C difficile Infection Clinical Guidance From IDSA/SHEA, Infectious Disease Advisor, February 2018

2New Clostridium difficile Guidelines, The Society for Healthcare Epidemiology of America, 2018

This webinar will:
  • Review the clinical background of C. difficile and its role as a pathogen in human health
  • Identify various ways in which C. difficile can be accurately diagnosed
  • Discuss the revised treatment recommendations for C. difficile
  • Evaluate the role of the 2018 modifications to the NHSN reporting criteria for healthcare-associated C. difficile
Nathan A. Ledeboer, PhD, D(ABMM)
Professor and Vice Chair of Pathology and Laboratory Medicine
Medical College of Wisconsin
Nathan Ledeboer Photo
Dr. Ledeboer is a Professor and Vice Chair of Pathology and Laboratory Medicine at the Medical College of Wisconsin and the Medical Director of Microbiology and Molecular Diagnostics for Wisconsin Diagnostic Laboratories and Froedtert Health. His research endeavors, particularly in the area developing diagnostic tools for infectious diseases, have led to more than 80 publications in peer-reviewed journals and more than 100 funded research projects. Dr. Ledeboer is also a senior editor for the Journal of Clinical Microbiology.
Overview of Lean Principles in Histology: Patient Safety, Efficiency, and Workflow
Live Event: Thursday, September 27, 2018  1:00 - 2:00 PM EST
PACE® Credit available until March 27, 2019  |  Florida Lab Credit available
Recording Slides
Lean six sigma principles have made their way into the anatomic pathology laboratory and applying lean tools and methods can have a positive impact on any size histology laboratory operation. When applied into everyday practice, lean can play a key role in a histology laboratory’s operational efficiency. Lean concepts can support continuous improvement initiatives that focus on patient safety, error proofing and reduction of waste. A histology laboratory can benefit from lean principles as they transition away from traditional specimen handling and processing methods moving towards implementation of small batch handling and continuous processing.

This presentation will serve as a basic introduction of lean principles as it is applied to histology practice. An overview of operational challenges of histology highlighting common practices that are lean improvement opportunities will be discussed. Participants will learn to evaluate histology processes from the lean perspective. Examples of lean applications to improve patient safety, specimen tracking, and case integrity will be shared.

After this presentation, participants will have a better understanding of best practice and basic lean concepts applied in the histology laboratory, and recognize common practices that are considered to be potential patient safety risks.

This webinar will:
  • Evaluate histology laboratory operational challenges
  • Define waste and discuss the ways of identifying it in histology
  • Identify common practice risks in the histology laboratory process
  • Describe basic lean fundamentals that support patient safety, efficiency, and workflow in histology

Christa Cappellano, BS, HT(ASCP)QIHC, LSSBB
CEO & Founder of coLABration Consulting, LLC
Christa Cappellano Photo
With 27 years of experience in pathology as a laboratory director, manager, and histotechnologist, she is a published textbook author in the field of Histotechnology and a workshop instructor/teacher at national conferences on subject matters of lean, laboratory performance metrics and histology technical practices. Christa served as a committee member of national organizations and regulatory agencies (ASCP, CAP, NSH).
The Patient-Centered Laboratory: A Renewed Focus
Live Event: Thursday, August 23, 2018  1:00 - 2:00 PM EST
PACE® Credit available until February 23, 2019  |  Florida Lab Credit available
Recording Slides
Laboratory testing is absolutely necessary for patient care, and the role of high-value diagnostics continues to increase in importance across the continuum of care. High quality, cost-effective and appropriately-utilized laboratory tests are essential in achieving healthcare’s Triple Aim. Triple Aim is a framework developed by the Institute for Healthcare Improvement (IHI) as an approach to optimizing health system performance. This framework encompasses three dimensions that must be pursued in order to have Triple Aim success1. This presentation will focus on the first dimension: improving the patient experience of care.

Today, the physician-centric model of “Doctor Knows Best” is no longer the only consideration. Have we ever asked the patient, “What will an abnormal result mean to you?” With the patient experience becoming the center, healthcare delivery systems must leave the status quo behind and develop processes that are intentionally focused on what is important to the patient. This focus will drive improvements in patient transactions, access and efficiency while managing costs; and when managed properly will create increased loyalty and help improve outcomes.

1IHI Triple Aim Initiative, Institute for Healthcare Improvement

This webinar will: 
  • Describe the difference between physician-centric and patient-centric laboratory testing
  • Identify the role that the laboratory has in achieving healthcare’s Triple Aim
  • Evaluate existing laboratory service delivery across the care continuum
  • Develop a plan to upgrade your laboratory to providing patient-centric services
Jane Hermansen, MBA, MT(ASCP)
Manager, Outreach and Network Development
Mayo Medical Laboratories
Jane Hermansen Photo
Jane Hermansen has over 30 years of clinical laboratory experience, within community hospital and academic medical center settings. At Mayo Clinic since 1988, she currently directs the outreach consulting and health plan contracting network activities for hospital laboratories across the country. Jane holds a B.A. in Medical Technology from Concordia College in Moorhead, Minnesota and a Masters of Business Administration degree from the New York Institute of Technology.
Creating Laboratory Value for a Competitive Advantage
Live Event: Wednesday, June 20, 2018  1:00 - 2:00 PM EST
PACE® Credit available until December 20, 2018  |  Florida Lab Credit available
 Recording Slides
In today’s evolving health care environment, clinical laboratories must make the transition from a fee-for-service model to fee-for-value models and patient’s centered models. With this shift, a new clinical and business model, known as Clinical Lab 2.0, is emerging for medical laboratories. Clinical Lab 2.0 takes a broader view of the value of laboratory medicine by encouraging laboratories to expand their services to provide integrated care across a health system1.

This session will present an illustrative case study on how FirstPath Laboratory, a South Florida lab providing state of the art diagnostic Anatomic Pathology services for the physicians and patients, has applied Clinical Lab 2.0 to address a pressing issue being faced today: what can be done to keep patients out of the hospital? By partnering with telemedicine services, FirstPath has been able to provide mobile bedside laboratory testing by licensed laboratory professionals. This service extends laboratory quality testing to the patients’ bedside resulting in significant cost savings, improved on-site patient care and ultimately reducing emergency room visits.

1Helping Medical Laboratories Add Value to Health Systems, Providers, and Payers by Moving from Clinical Lab 1.0 to Clinical Lab 2.0, Dark Daily

This webinar will: 
  • Illustrate how clinical laboratories can use Clinical Lab 2.0 as a path to adding value
  • Describe the need for clinical laboratories to expand services outside of usual practice
  • Identify opportunities in their institutions where integrated care can be applied
  • List the ways in which a lab can apply Clinical Lab 2.0 philosophy to yield cost savings and improved patient care
Leo Serrano, FACHE, DLM (ASCP) CM,
Clinical and Operational Consultant, FirstPath LLC
Leo Serrano photo
Leo Serrano, is the Clinical and Operational Consultant for FirstPath LLC located in Pompano Beach, Florida and a recognized thought leader and international speaker on Clinical Laboratory Medicine. He has over 50 years of laboratory management experience with an expertise in a number of clinical specialties. A Lean Six Sigma Black Belt, Leo directed the first U.S. hospital laboratory to achieve ISO-14189 accreditation, which re-accredited for a second cycle.
Laboratory Stewardship: The Power of Appropriate Test Utilization
Live Event: Wednesday, May 23, 2018  1:00 - 2:00 PM EST
PACE® Credit available until November 23, 2018  |  Florida Lab Credit available
Recording Slides

Laboratory Stewardship has proven to be one of the most successful strategies used by hospitals and laboratories to:

1. Improve the quality of patient care
2. Optimize resources
3. Reduce waste

This session will focus on these three key areas and present interesting case studies that highlight how some organizations are leveraging laboratory stewardship in ways that benefit hospitals, providers, and patients including:
  • Improving the quality of care and extending length of life by decreasing mortality rates
  •  Aligning laboratory testing with drug therapy to measure patient response and decrease pharmacy spend
  •  Reducing over-utilization and driving cost savings by working with physicians to identify and implement charge savings opportunities

Participants will leave this session with a broadened knowledge of laboratory stewardship that supports implementation and measurement of successful interventions. Moreover, participants will understand that ‘utilization management’ is just one component of laboratory stewardship.

This webinar will: 
  • Describe the difference between utilization management and laboratory stewardship
  • Identify critical factors for success in implementing laboratory stewardship interventions
  • Differentiate low impact versus high impact interventions
  • Cite ways in which laboratory stewardship moves the dial on patient care and outcomes
Suzanne Carasso, MBA, MT (ASCP), Director, Business Solutions Consulting
ARUP Laboratories
Suzanne Carasso photo
Suzanne Carasso, a medical technologist, has leveraged extensive technical and managerial experience in the clinical lab to transition into healthcare consulting. She is currently employed by ARUP Laboratories. Specific areas of expertise include strategic business planning for integration and consolidation of laboratory services, evaluation of laboratory operational models, laboratory stewardship, and outreach development. Suzanne also speaks at regional and national laboratory meetings and is a published author in a variety of healthcare journals.
The Laboratorian as a Clinical Consultant: Identifying Needs
and Building New Roles
Live Event: Wednesday, April 25, 2018  1:00 - 2:00 PM EST
PACE® Credit available until October 25, 2018  |  Florida Lab Credit available
Recording Slides
The clinical laboratory’s essential role in healthcare is growing in importance as the bridge between advances in the basic sciences and clinical practice. Bringing our knowledge to the individual patient care encounter by serving as clinical consultants is an important goal. The principal aim is to improve patient care while demonstrating the value of clinical laboratorians in expanded roles. As expectations in healthcare put increasing emphasis on quality and cost-effectiveness, there are real opportunities for clinical laboratorians to expand your sphere of influence within your organizations, but these can be a challenge to achieve. What strategies are available, and how does one build and expand a consultant role within a health care organization?

This webinar will highlight the need for increasing your role as consultants in the clinical care process, as leaders in laboratory resource utilization, and as leaders in hospital quality initiatives.

This webinar will: 
  • Describe the need for clinical laboratorians to expand their sphere of influence outside the walls of the clinical laboratory
  • Identify opportunities in institutions for expanding the professional role of clinical laboratorians
  • Identify key clinical and administrative partners for a successful program that fully utilizes the skill set of the laboratorian
  • Discuss the key areas in which laboratorians can partner with care teams to improve patient care
Anthony A. Killeen, MD, PhD
Ellis S. Benson Professor and Vice-Chair for Clinical Affairs
Dept. of Laboratory Medicine & Pathology, University of Minnesota
Tony Killeen Photo
Dr. Killeen is the Ellis Benson Professor of Laboratory Medicine and Vice-Chair of the Department of Laboratory Medicine and Pathology at the University of Minnesota in Minneapolis. He received his undergraduate and medical degrees from the National University of Ireland at Galway.
Diagnosing Group A Strep pharyngitis: Which Technique is Best for You?
Live Event: Tuesday, March 27, 2018  1:00 - 2:00 PM EST
PACE® Credit available until September 27, 2018  |  Florida Lab Credit available
 Recording Slides
Acute pharyngitis is responsible for 15 million sick visits per year in the United States, with Group A strep accounting for 20-30% of pediatric and 5-15% of adult cases1. If not accurately diagnosed and treated, it can also lead to more serious complications, especially in the pediatric population.

This presentation will cover the various ways in which a diagnosis of Group A Strep can be achieved. Traditional microbiology laboratory workup will be covered, as well as molecular techniques for diagnosis along with Point-of-Care (POC) testing techniques. Included within this presentation will also be the recommendations by the Infectious Disease Society of America related to lab workup and treatment for Group A Strep. The webinar will also discuss testing cost and how it relates to decisions on which testing methodologies to utilize within your laboratory.

1Shulman et al., Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal pharyngitis: 2012 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases 2012;55(10):e86–102

This webinar will: 
  • Review the clinical background on Group A Strep and its role as a pathogen in human health
  • Identify various ways in which Group A Strep pharyngitis can be accurately diagnosed
  • Discuss testing recommendations for Group A Strep pharyngitis
  • Examine aspects that influence which test(s) are the best fit for a clinic/health system
Gregory J. Berry, Ph.D., D(ABMM),
Assistant Professor of Pathology and Laboratory Medicine
Zucker School of Medicine at Hofstra/Northwell

Gregory J. Berry is a Diplomate of the American Board of Medical Microbiology and an Assistant Professor of Pathology and Laboratory Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. He is also the Director of Molecular Diagnostics and an Assistant Director of Infectious Disease Diagnostics at Northwell Health Laboratories in New York.
Closing the Gap in Pre-analytical Specimen Quality
Live Event: Tuesday, February 27, 2018  1:00 - 2:00 PM EST
PACE® Credit available until August 27, 2018  |  Florida Lab Credit available
Recording Slides
Assessment of laboratory quality is broken down into 4 phases; general, pre-analytical, analytical, and post-analytical. While the laboratory has control over the general (safety, policies, proficiency testing) and analytical portions, pre-analytical and post-analytical quality are often outside of their hands. Post-analytical quality refers to the processes that occur after the lab testing is completed including patient reports, communication and complaints. Pre-analytical specimen integrity is just as critical to the result reported by the laboratory. The laboratory must have processes in place to educate the customer on specimen collection, specimen storage and specimen transport. The laboratory must also have processes in place to identify when to reject specimens based on improper collection, storage and/or transport, and to communicate back to the customer in a manner which will provide education for improved specimen quality.

This webinar will: 
  • Explain the importance of proper collection, transport, and storage of specimens
  • Identify collection, transport and storage concerns in their own laboratory
  • Outline improvements needed to improve pre-analytical quality in their own laboratory
  • Assess and evaluate the impact of these improvements

Margaret Blaetz, CLC(AMT), CCCP(AAPOL)
CEO, East Coast Clinical Consultants
Margaret Blaetz Photo
Margaret Blaetz began her career as a Medical Laboratory Technician specializing in Microbiology and obtained her Bachelor of Science Degree at Glassboro State College (Rowan University). Her 30+ year career in laboratory science includes clinical laboratory management, sales and customer service for a national laboratory, and research and development of diagnostic test kits.
2018 Outlook for the Clinical Laboratory Industry
Live Event: Wednesday, January 31, 2018  1:00 - 2:00 PM EST
PACE® Credit available until July 31, 2018  |  Florida Lab Credit available
Recording Slides  
Following a year of sending mixed policy signals to the healthcare industry, including the clinical laboratory sector, Washington policymakers will be grappling with a host of healthcare issues in 2018. These issues will range from key decisions impacting the Affordable Care Act to potential budget cuts affecting the Medicare and Medicaid programs.

This presentation will examine the latest national policy developments and trends affecting clinical labs. This includes the outlook for a new Medicare market-based national fee schedule that would make major payment cuts for many lab tests, how Medicaid and commercial insurer reimbursement to labs will be influenced by the changeover to Medicare market-based rates, the status of laboratory developed test oversight by Congress and the Food and Drug Administration, and lastly, the leading Washington policy challenges for the lab industry in the year ahead.

This webinar will: 
  • Analyze the latest policy initiatives affecting the Affordable Care Act for the short and longer term.
  • Discuss the outlook for federal budget cuts to Medicare and Medicaid and the impact they would have on both beneficiaries and providers, including labs.
  • Review the status of a new Medicare market-based payment system for lab testing and how payment rates will change starting in 2018.
  • Identify top federal policy challenges for labs over the next year.
Dennis Weissman
President, Dennis Weissman & Associates, LLC
Dennis Weissman Photo
A nationally known, independent analyst, consultant and thought leader for the clinical laboratory and anatomic pathology sectors for over three decades, Dennis is President of Dennis Weissman & Associates, LLC, Falls Church, VA, a consultancy which provides market intelligence, M&A advisory services, business leadership and public policy advice to diagnostic and life science companies and organizations. Mr. Weissman has expertise in Medicare and health care reform policies and trends; clinical laboratory and pathology payment & compliance policies as well as business trends affecting the diagnostic sector.
The First Cut isn't the Deepest: Proposed Clinical Lab Fee Schedule
under PAMA
Live Event: Wednesday, December 13, 2017 1:00 - 2:00 PM EST
PACE® Credit available until June 13, 2018  |  Florida Lab Credit available
Recording Slides
On June 23, 2016, the Centers for Medicare & Medicaid Services (CMS) released a final rule implementing Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA). This legislation creates a single, national fee schedule which is based upon private payor rates. Applicable laboratories performing clinical diagnostic laboratory tests had to report the amounts paid by private insurers for laboratory tests. Medicare then used the weighted median of private insurer rates to calculate Medicare payment rates for laboratory tests paid under the Clinical Laboratory Fee Schedule (CLFS) beginning January 1, 2018.

CMS initially estimated that using a market-based system stipulated under PAMA would save $390 million in the first year of 2018, and $3.93 billion over a decade1. In September 2017, CMS released the proposed new rates and the rate cuts are more significant than originally anticipated. The proposed rate structure would result in reductions of $670 million in Part B program payments for clinical lab fee schedule (CLFS) tests in 20182. The preliminary rate schedule introduces dramatic cuts. 58% of tests will have reductions phased in over multiple years as the preliminary rates exceed the maximum per year reduction3.

This new rate structure represents a dramatic shift in the way laboratory tests are reimbursed. This webinar will provide clinical laboratories with an update on the implementation of the new Clinical Lab Fee Schedule and the financial impact to clinical labs.

1PAMA Regulations, CMS, September 19, 2016
2CMS 2018 PAMA Pricing Cut for Lab Tests Deeper Than Prior Estimate; Advanced Dx Lab Tests Fare Well, GenomeWeb
3CY2018 – Preliminary Private Payor Rate-Based CLFS Payment Rates and Analytics, available at

This webinar will: 
  • Discuss the changes to payment rates for tests paid on the Clinical Lab Fee Schedule.
  • Identify the 2018 payment rates for CPT codes including which codes are increasing/decreasing.
  • Recognize which CPT codes will have phased in rate reductions due to per annum caps.
  • Identify the payment changes to panel based tests, molecular diagnostic tests, etc.
  • Illustrate the impact to your clinical laboratory based upon the 2018 rates.
Chandra Branham Photo Chandra Branham, J.D., VP

Chandra Branham, J.D., joined the Advanced Medical Technology Association (AdvaMed) as Vice President, Payment and Health Care Delivery Policy, in 2011.

Julie Khani Photo Julie Khani, President

Julie Khani became president of the American Clinical Laboratory Association (ACLA), the largest organization representing the public policy interests of laboratories, in 2017.

Data Hidden in Plain Sight: Using Unexpected Analytics for Quality and
Process Improvement in the Clinical Laboratory
Live Event: Thursday, November 16, 2017 1:00 - 2:00 PM EST
PACE® Credit available until May 16, 2018  |  Florida Lab Credit available
Recording Slides
Clinical laboratories are swimming in data. However, many opportunities for improvement in the laboratory may go unrecognized. Studies are performed and actions are taken on common metrics like turn-around time and test volume while other, potentially more revealing metrics receive little focus. Workflows and activities such as specimen flow, testing protocols and pre-authorizations linked to the EHR, and blood utilization tactics are examples of where opportunities exist to uncover operational efficiencies and cost savings.

The ability of the clinical laboratory to effectively utilize available data will become increasingly important as the laboratory faces challenges on staffing and reimbursement. Opportunities also exist for laboratorians to utilize the data generated in their laboratories to educate providers, care teams, and patients which positively impacts patient care. This webinar will describe three different projects that utilized unexpected data points to affect change to the laboratory workflow and clinical care.

This webinar will: 
  • Discuss sources of unexpected data in the laboratory and how they can be used for improvement efforts.
  • Identify the need for data to support improvement efforts or implementing change.
  • Describe a process whereby current data sources can be tweaked for use in specific improvement activities.
  • Define financial and operational benefits associated with utilizing unexpected sources of lab data.
Jordan Olson MD FCAP
Medical Director Clinical Pathology Informatics
Geisinger Medical Center
Jordan Olson Photo
Jordan Olson is the medical director for clinical pathology informatics in the Geisinger Medical Laboratory, the medical director of pre-analytics and phlebotomy, and the medical director for the Geisinger Bloomsburg Hospital laboratory. Dr. Olson completed his undergraduate and medical school at the University of Wisconsin-Madison School of Medicine and Public Health.
Survival of the Fittest: Transforming Your Lab from Cost to Value Center
Live Event: Wednesday, October 18, 2017 1:00 - 2:00 PM EDT
PACE® Credit available until April 18, 2018  |  Florida Lab Credit available
Recording Slides
The new era of healthcare reform is here. Not only is there no going back, but maintaining status quo in healthcare organizations that operate inefficiently is a costly and unsustainable business model. Now is the time to adopt a new way of thinking and behaving around cost containment. Healthcare systems that get it will survive. Those that don’t likely won't.

Laboratory testing plays a central role in healthcare delivery that impacts both costs and outcomes. Unfortunately in some organizations, the laboratory is viewed as little more than a cost center that runs tests and reports results. In order to change this perception, labs must demonstrate quantifiable value well beyond the delivery of test results. When labs actively engage with clinicians to educate, inform, and support optimal test utilization, the transition from cost to value center has begun.

Utilization management has come to the forefront as an effective way to optimize laboratory testing in ways that benefit patients first and foremost, while driving down the overall cost of care. This presentation will discuss the components of an effective utilization management program. The speaker will present a roadmap for improving utilization management, provide specific examples of successful approaches, and highlight opportunities for improvement.

This webinar will: 
  • Identify industry trends driving the transition from volume to value-based healthcare.
  • Discuss key metrics associated with inappropriate test utilization.
  • Describe five components of the utilization management roadmap.
  • Cite successful strategies, beyond laboratory formulary, to optimize test utilization.
  • Define ways in which laboratories operate as value centers.

Suzanne Carasso, MBA, MT(ASCP), Director, Business Solutions Consulting with ARUP Laboratories
Suzanne Carasso
Suzanne is currently Director, Business Solutions Consulting with ARUP Laboratories. ARUP is a leading national reference laboratory owned by the University of Utah. As spokesperson for ARUP Laboratories Consulting Division, Suzanne works with a variety of organizations across the United States including large academic medical centers, integrated delivery networks, multi-hospital health systems, community hospitals, children’s hospitals, independent laboratories and group purchasing organizations.
FDA’s New Reclassification of Rapid Influenza Diagnostic Tests: Are you Prepared?
Live Event: Wednesday, September 27, 2017  1:00 - 2:00 PM EDT
PACE® Credit available until March 27, 2018  |  Florida Lab Credit available
 Recording Slides
Earlier this year, the U.S. Food and Drug Administration (FDA) published a final rule that reclassifies antigen-based Rapid Influenza Diagnostic Tests (RIDTs) from Class I to Class II and requires that these diagnostic devices meet increased sensitivity, specificity and annual strain testing quality controls. This reclassification becomes effective on January 12, 2018, which will have implications for laboratories during this upcoming influenza season (2017/2018).

This device reclassification was driven by concerns from the Centers for Disease Control and Prevention (CDC) about test sensitivity of RIDTs during the 2009 pandemic flu season. The goal of the reclassification is to improve the overall performance of RIDTs by requiring additional regulatory controls. These new measures should reduce the incidence of false-negative results, improving antibiotic stewardship across the continuum of care.

This webinar will review the FDA reclassification of RIDTs, discuss the new sensitivity and specificity requirements for RIDTs, and provide an overview of the products on the market that meet the new requirements. Also covered in the webinar will be information on how long products not meeting the new requirements can be sold by distributors and manufacturers, as well the date up until which laboratories may use such diagnostic devices. This webinar is intended to help enable laboratories to prepare for the changes and minimize any impacts to established influenza protocols.

This webinar will:
  • Review FDA influenza reclassification requirements and assess impact to currently utilized RIDTs
  • Identify the different types of influenza tests available and if they are compliant with the new FDA guidelines
  • Understand the pros and cons of each type of influenza testing based on the needs of your laboratory
  • Explain the dates until which products not meeting the new guidelines can by sold, as well as how long they can be used for patient testing

Click here to learn more about Cardinal Health’s influenza testing platforms that ensure FDA compliance.

Click here to download questions and answers from this webinar.
Gregory J. Berry, Ph.D., D(ABMM)
Assist. Prof., Pathology and Lab. Medicine
Hofstra Northwell School of Medicine
Greg Berry photo
Gregory J. Berry Ph.D., D(ABMM) is an Assistant Professor of Pathology and Laboratory Medicine at Hofstra Northwell School of Medicine and an Assistant Director of Infectious Disease Diagnostics at Northwell Health Laboratories in New York. He is also a Diplomate of the American Board of Medical Microbiology.
Six Trends that will Change Health Care over the Next 5 Years
Live Event: Wednesday, August 30, 2017  1:00 - 2:00 PM EDT
PACE® Credit available until February 30, 2018  |  Florida Lab Credit available
Recording Slides  
The dynamics of the healthcare are that the industry will continue to be fluid, with evolution and change continuing for the next several years. Beyond healthcare policy, change will be driven by multiple factors. These factors range from value-based care to technology and data to the demographics of the people accessing care. The macro trends identified will impact the industry as whole, but have downstream implications and opportunities for the clinical laboratory. The role of the laboratory is evolving relative to patient care as well as how it supports the goals and initiatives of its hospital or healthcare system. This shifting role requires laboratories to think differently and quickly respond to the changes in their environment. Considerations for the laboratory include how to better utilize the data they generate, the expanding role of precision medicine, and addressing how millennials want to consume healthcare and diagnostic testing.

This webinar will outline the six trends that will change healthcare in the next 5 years. These trends were identified as a result of a multi-faceted study conducted by Huron Consulting Group and have several downstream implications to the clinical laboratory. By recognizing the opportunities that exist for the laboratory in response to these trends, the laboratory will be well positioned to create value within their system.

This webinar will:
  • Discuss the major trends impacting healthcare over the next 5 years and the impacts to the laboratory
  • Identify how the laboratory can adapt to these changes and create value for its stakeholders
  • Determine how risk and value-based care models impact the laboratory
  • Recognize the shifting requirements of patient populations 
 Ted Schwab photo Ted Schwab, Managing Director, Huron Healthcare Practice
Huron Consulting Group Inc

Ted is an industry leader in innovation through his work with clinicians, executives, and governing bodies around the country, helping them design the next generation of healthcare organizations.

K.R. Prabha photo  K. R. Prabha, Senior Director, Healthcare Strategy
Huron Healthcare Practice
Huron Consulting Group Inc  

Prabha brings over 15 years’ consulting experience focused on care delivery strategy, innovation, and measurable improvements in access, quality, cost, and patient experience.
What's Your Cost of Poor Quality? Calculating an ROI for Your Lab's Quality Program
Live Event: Wednesday, June 21, 2017  1:00 - 2:00 PM EDT
PACE® Credit available until December 21, 2017  |  Florida Lab Credit available
Recording Slides
Within the clinical laboratory, quality has multiple components. The most thought of component of quality relates to CAP (College of American Pathologists) inspections, accreditations, and standard regulatory compliance activities. Clinical laboratories often struggle to justify the resources to adequately support quality management and regulatory compliance programs. Many times this is due to lab quality efforts being viewed as a costly and necessary evil to achieving regulatory compliance. What often goes unrecognized are how quality management programs can be utilized to drive expense out of laboratory operations. For example, robust quality management programs can help reduce expenses associated with lost specimens, repeat testing and reagent management.

This session covers the concept of Cost of Quality, but focuses on the cost of poor quality (CoPQ). Methods for labs to calculate and capture CoPQ will be discussed. Armed with actual CoPQ data, laboratories can begin to speak the language of the "C Suite" by demonstrating improvement in financial performance. Labs can begin to portray their quality programs as mechanisms to achieve cost savings and cost avoidance, in addition to the quality, regulatory and patient safety benefits that are already well recognized.

This webinar will: 
  • Discuss the concept of Cost of Quality and its components.
  • Differentiate between hard and soft costs associated with quality management.
  • Review methodologies to capture and track Cost of Poor Quality (CoPQ).
  • Analyze how labs can use CoPQ data to demonstrate a return on investment for their quality efforts.
Jennifer Dawson photo
Jennifer Dawson is Senior Director, Quality for Human Longevity, Inc in San Diego, CA where she is responsible for building a best practice Quality Management System as well as for CLIA compliance and obtaining CAP and CAP 15189 accreditation. She formerly served as Vice-President Quality for Sonic Healthcare USA and was responsible for developing their quality management system.
Using Lab Information to Reduce Downstream Healthcare Costs: Case Studies
Live Event: Wednesday, May 17, 2017  1:00 - 2:00 PM EDT
PACE® Credit available until November 17, 2017  |  Florida Lab Credit available
Recording Slides
Laboratory testing provides more than just a snapshot of a patient’s medical condition at any point in time. Leveraging the power of the information provided by the laboratory can have significant impact on other downstream costs within the health care ecosystem and beyond to community health.

This webinar will provide case studies on how laboratory information is being used at a large integrated health care delivery system to lower cost and improve patient outcomes. Case studies will discuss how the data generated by the laboratory can help educate patient care teams, streamline/optimize test ordering, and provide visibility to patient adherence.

This webinar will: 
  • Analyze the “real” value of laboratory information
  • Identify sources of concrete examples of where laboratory information provides downstream value
  • Evaluate new financial models for laboratory reimbursement and/or cost containment
  • Discuss the most effective ways to become an advocate for laboratory testing
Ran Whitehead, CEO, PeaceHealth Laboratories
Ran Whitehead photo
Ran Whitehead is the Chief Executive Officer at PeaceHealth Laboratories. He has enhanced the company’s reputation for technical and clinical excellence, collaborative partnerships, and innovative programs. Ran has led initiatives such as a distance learning program that was later adopted by laboratories across the country.
Actions You Can Take to Have Your Lab Viewed as a Profit Center
Live Event: Wednesday, April 18, 2017  1:00 - 2:00 PM EDT
PACE® Credit available until October 18, 2017  |  Florida Lab Credit available
 Recording Slides
As clinical management and lab operators, your day may be consumed with daily operational or service issues. Some days, it’s about all you can do to get through one more day. It is hard to set aside time to think strategically or understand what your laboratory management executive is thinking. This webinar will reveal the 5 steps you can take to create value and change the perception of your laboratory and outreach programs by hospital and health system executives.

This webinar will: 
  • Demonstrate an understanding of today’s market and business trends and how they can be used to provide strategic and financial value to your clinical laboratory
  • Identify actions you can take that can help various medical and laboratory executive stakeholders think differently about your laboratory operations
  • Apply relevant strategies to position yourself and your lab proactively for change and growth based on changing healthcare dynamics.

Click here to download the article referenced by Dr. Murphy, Good News and Bad News in PAMA Final Rule for Repricing Lab Tests, shared with permission from Laboratory Economics.
Kathleen A. Murphy, PhD, Senior Growth Advisor Chi Solutions, Inc.

Kathleen Murphy photo
Kathleen A. Murphy, PhD, Senior Growth Advisor for Chi Solutions, Inc., an Accumen company, is a noted laboratory expert, speaker, and author. Over her 35 years in laboratory management and consulting, including her former role as the CEO of Chi, Dr. Murphy has gained broad industry experience in laboratory strategy, turnarounds, and outreach. She is the author of The Profit Machine in the Hospital Basement: Turning Your Lab into an Economic Engine (Ellsworth Press, 2016).
How Effective Test Utilization Can Support Patient Safety
Live Event: Wednesday, March 29, 2017  1:00 - 2:00 PM EDT
PACE® Credit available until September 29, 2017  |  Florida Lab Credit available
Recording Slides 
Utilization of laboratory services is of constant concern because of the cost to our health care system, the drain on laboratory resources, and the waste of valuable time in diagnosing, treating and managing patients. A recent article in the Journal of the American Medical Association (JAMA) suggests that there are also patient safety issues that must be considered.

This webinar will report on the progress of the CDC project known as the Clinical Laboratory Integration into Healthcare Collaborative (CLIHC). This project has been examining how physicians order laboratory tests, what they need to be able to order appropriately and what gaps need to be filled by laboratory professionals. These projects give us a better understanding on what clinicians know about laboratory science and medicine. This presentation will also examine several different approaches to controlling utilization and discuss how to implement utilization programs. The “how” is very dependent on many factors, several of which will be described, that exist in every healthcare setting.

This webinar will: 
  • Describe the Clinical Laboratory Integration into Healthcare Collaborative (CLIHC) project.
  • Discuss instances of miscommunication, poor utilization of laboratory services and patient consequences.
  • Analyze barriers and solutions currently being discussed in various institutions.
  • Evaluate implementation processes that might be useful in your setting.

Elissa Passiment, MT(ASCP), EDM
Senior Partner, EP Clinical Laboratory Consulting
Elissa Passiment photo
Elissa Passiment is a clinical laboratory scientist with over twenty years’ experience in clinical laboratories as staff, educator and manager and another twenty years in health care consulting, association management and health policy.
Ms. Passiment has served on the congressionally mandated Negotiated Rulemaking Committee convened to standardize and simplify reimbursement for laboratory services under Medicare Part B; presented testimony to Institute of Medicine studies, and represents ASCLS at meetings with the FDA, CMS, and CDC.
Laboratory Test Utilization: Improving Outcomes and Reducing Costs
Live Event: Tuesday, February 28, 2017  1:00 - 2:00 PM EST
PACE® Credit available until August 28, 2017  |  Florida Lab Credit available
Recording Slides
The nation’s healthcare system has been steadily shifting from fee-for-service to fee-for-value models and patient’s centered models. This transition has created opportunities for clinical diagnostic laboratories to partner within their healthcare systems on initiatives, such as improved patient outcomes, lowering readmission rates, and reducing the cost of patient care. This approach not only provides benefit to patients and the healthcare system but also enables laboratories to play a more integrated role in the care of patients.

With the rapid advancement of molecular diagnostic testing, there is an increasing need for the laboratory to provide education and decision algorithms to help mitigate unnecessary testing. Creating guidelines to help clinicians navigate the increasingly complex landscape of molecular diagnostics is another opportunity for the laboratory to support the transition to value based care.

Optimal utilization of laboratory testing and the implementation of clinician decision support tools have enabled numerous healthcare systems to lower their laboratory testing expenditures and improve patient care associated with high-risk infections and conditions. The mechanisms for achieving, and the benefits associated with, proper laboratory test utilization can be achieved in a variety of ways. Critical to the success of laboratory test utilization programs is partnering with providers in the development of test plans and protocols. Utilizing a collaborative approach across the organization will help ensure adoption and adherence to new protocols.

This presentation will provide information on the how clinical laboratories can utilize testing protocols to help their healthcare systems to reduce costs and achieve goals associated with CMS’ Core Measures and Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) scores. The benefits of enhanced utilization of laboratory testing and the utilization of decision support tools to enable improved patient outcomes will be discussed. Considerations and best practices for effective implementation and adoption of laboratory test utilization programs will be reviewed.

This webinar will: 
  • Identify how the laboratory can partner with stakeholders across the healthcare system to reduce healthcare costs by properly utilizing laboratory tests.
  • Define how laboratory test utilization and decision support tools can enable clinicians to improve patient outcomes.
  • Demonstrate how the laboratory can be utilized to address the transition from fee-for-service to fee-for-value
To download the Quality Chasm Series: Health Care Quality Report, click here.
Eugenio Zabaleta, Ph.D.
Clinical Chemist, OhioHealth Mansfield Hospital
Eugenio Zabeleta pic
Eugenio H. Zabaleta, PhD, is a Clinical Chemist at OhioHealth Mansfield Hospital. He is also Part-time Lecturer at Cleveland State University Graduate Clinical Chemistry Program in Cleveland, OH. He graduated from the Catholic University of Cordoba (Argentina) with a degree in Biochemistry and received his PhD in Chemistry from the University of Akron. His training in Clinical Pathology was at the Hospital Provincial San Roque in Cordoba. In his native country he was the Laboratory Medical Director at the Clinica Del Sol, a clinic devoted to mother-and-child care with neonatology intensive care services. Dr. Zabaleta performed a fellowship at OhioHealth Mansfield Hospital Laboratory.
Compliance Considerations for Clinical Laboratories
Live Event: Wednesday, January 25, 2017  1:00 - 2:00 PM EST
PACE® Credit available until July 25, 2017  |  Florida Lab Credit available
Recording Slides
Clinical laboratories provide valuable testing services to their institutions, patients and communities but are operating in increasingly complex and competitive environments. Healthcare reform continues to evolve and with this comes a responsibility by both the laboratories and clinicians to understand the compliance requirements associated with providing testing services. Violation of the laws can put both the laboratory and clinician at risk for criminal and civil penalties. Understanding the state and federal statutes associated with marketing testing services to new and existing clients will enable clinical laboratories to identify risks associated with kick-backs and fraud and abuse. To ensure proper use of funds, Medicare and private payors are increasing the frequency and depth of the audits to clinical laboratories. These audits are being performed to ensure medical necessity, proper utilization of specific test codes and types, as well as proper collection of co-pays and co-insurance. By understanding the laws and guidelines, clinical laboratories can develop robust compliance programs to reduce risks and provide transparency to their healthcare system, clients and payor network.

This presentation will provide an overview to the key laws and statutes as well as address a variety of compliance requirements that clinical laboratories must adhere to mitigate legal and financial risks. Compliance requirements and common issues related to laboratory billing will be identified. Examples of non-compliance will be reviewed. Also addressed within the presentation will be the risks clinical testing laboratories commonly have associated with payor audits.

This webinar will: 

  • Interpret how the Stark Law framework, anti-kickback statute, and exception to limitations applies to laboratory testing
  • Discuss the developments in compliance requirements for client account billing for laboratory testing
  • Identify risks and issues commonly associated with payor audits
Elizabeth Sullivan, Esq.
McDonald Hopkins LLC
Liz Sullivan Photo
Elizabeth Sullivan is a member of the firm’s National Healthcare Practice. She began her legal career as an associate in the Healthcare Practice group and recently returned to McDonald Hopkins. For the past four years, Liz served as associate counsel for The Cleveland Clinic Foundation where she provided regulatory advice and transactional guidance to various service lines, including the clinical laboratory, professional pathology, imaging, transplant, and remote and distance health teams. During her career, Liz has assisted clinical laboratories, hospitals, physician specialty groups, telehealth providers, transplant centers, surgery centers, healthcare associations, pharmacies, and other healthcare providers on regulatory, licensing, compliance, reimbursement, contractual, and corporate matters.
Clinical Lab Payment Reform under PAMA: Reimbursement, Reporting and your New Responsibilities
Live Event: Wednesday, November 16, 2016  1:00 - 2:00 PM EST
PACE® Credit available until May 16, 2017  |  Florida Lab Credit available
Recording Slides

On June 23, 2016, the Centers for Medicare & Medicaid Services (CMS) released a Final Rule implementing Section 216 of the Protecting Access to Medicare Act of 2014 (PAMA), requiring laboratories performing clinical diagnostic laboratory tests to report the amounts paid by private insurers for laboratory tests. Medicare will use these private insurer rates to calculate Medicare payment rates for laboratory tests paid under the Clinical Laboratory Fee Schedule (CLFS) beginning January 1, 2018.*

The Final Rule not only reforms reimbursement for clinical laboratory testing but also has numerous requirements and components that laboratories need to understand and comply with. Noncompliance with these new requirements can have financial impacts on the laboratory/institution. Defined within the legislation are elements such as:

  • Definition of applicable laboratories required to report to CMS
  • Reporting periods, applicable information to be reported, and designated reporting authorities
  • Definition of advanced diagnostic laboratory tests (ADLTs) and how they differ in reporting and rate setting

This presentation will address important provisions of the law, including the new data reporting responsibilities for applicable laboratories, details about and timeframes for reporting private payer information, and information on the annual rate reductions allowed under the legislation. The presentation will also help laboratories translate the Final Rule to identify required actions and potential impacts for their laboratories.

*PAMA Regulations, CMS, September 19, 2016


This webinar will: 

  • Interpret the provisions of the Final Rule of Section 216 of PAMA which reforms payment to laboratory tests paid under the Clinical Lab Fee Schedule.
  • Identify and apply the new reporting responsibilities for their laboratory and understand the reporting timeframes and the impact it will have on their laboratory.
  • Recognize the methodology and opportunities to engage with CMS on the proposed payment rates before they become final.
Chandra Branham, J.D., VP
Advanced Medical Technology Association
Chandra Branham Photo
Ms. Branham leads the AdvaMed’s policy work in a number of areas, including diagnostics payment, coverage issues, and comparative effectiveness. Ms. Branham has spent most of her career focusing on healthcare regulatory and legislative issues involving Medicare coverage, coding, reimbursement and quality for providers and suppliers of Medicare items and services, including serving as a senior legislative analyst in the Centers for Medicare & Medicaid Services (CMS) Office of Legislation.

Julie Khani, Executive VP
American Clinical Laboratory Association
Julie Khani photo
Julie Khani joined the American Clinical Laboratory Association, ACLA, in 2013 as Senior Vice President, and was named Executive Vice President in 2016. In her current role Ms. Khani oversees the advocacy, policy and communications functions at ACLA and leads association efforts on implementation of the Clinical Laboratory Fee Schedule (CLFS) provisions of the Protecting Access to Medicare Act.

Whitehat Communications is approved as a provider of continuing education programs in the
clinical laboratory sciences by the ASCLS P.A.C.E.
® Program.

Cardinal Health is approved as a provider of continuing education programs in the
clinical laboratory sciences by the ASCLS P.A.C.E.
® Program.

These webinars are sponsored by
Cardinal logo 
© 2018 | Whitehat Communications, a division of Martek Inc.